Cargando…

The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review

PURPOSE: Gastrointestinal (GI) microbiome modulators, such as fecal microbiome transplants (FMTs), are being considered as supplements to standard immune checkpoint inhibitor (ICI) treatment to improve efficacy. This systematic review aims to assess the study design and outcomes of clinical trials t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatt, Anjali, Haslam, Alyson, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374733/ https://www.ncbi.nlm.nih.gov/pubmed/36928160 http://dx.doi.org/10.1007/s00432-023-04656-8

Ejemplares similares

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Medical Reversals in Family Practice: A Review
por: Haslam, Alyson, et al.
Publicado: (2020)

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
por: Rezasoltani, Sama, et al.
Publicado: (2020)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals
por: Haslam, Alyson, et al.
Publicado: (2023)

Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Yifan, et al.
Publicado: (2023)

Gut microbiome in modulating immune checkpoint inhibitors
por: Li, Xiang, et al.
Publicado: (2022)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
por: Mazloom, Anita, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

Characteristics of Facebook’s third-party medical fact checkers
por: Haslam, Alyson, et al.
Publicado: (2022)

Comparability of Control and Comparison Groups in Studies Assessing Long COVID
por: Haslam, Alyson, et al.
Publicado: (2023)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors
por: Patel, Priyanka, et al.
Publicado: (2021)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
por: Haslam, Alyson, et al.
Publicado: (2023)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival
por: Alomari, Mohammad, et al.
Publicado: (2022)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature
por: Haslam, Alyson, et al.
Publicado: (2022)

The frequency of assessment of progression in randomized oncology clinical trials
por: Haslam, Alyson, et al.
Publicado: (2021)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)

A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract
por: Liao, Xuqiang, et al.
Publicado: (2022)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
por: Dobosz, Paula, et al.
Publicado: (2022)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
por: Hwang, Sung Wook, et al.
Publicado: (2023)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nhsb5j5tskujf1mqs64toufu5f